Sobi publishes its report for the first quarter 2017

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the first quarter 2017. Total revenues amounted to SEK 1,396 M, an increase of 10 per cent compared to Q1 2016. Total revenue growth was 47 per cent adjusted for the one-time credit of SEK 322 M received in Q1 2016. Product sales amounted to SEK 1,269 M, an increase of 15 per cent, (61 per cent adjusted). Elocta® sales of SEK 250 M, and Alprolix® sales of SEK 50 M in the Sobi territory were complemented by strong performance across the portfolio.

Business highlights Q1 2017

• First patients enrolled in a 24 month real-world study for Elocta
• EMA approved higher capacity of drug substance manufacturing for Elocta
• New data for Alprolix published in Lancet Haematology, and in Thrombosis and Haemostasis
• Haemophilia B development portfolio was expanded by adding rF9Fc-XTEN for subcutaneous injection to the collaboration agreement with Bioverativ
• Health Canada approved Orfadin® capsules for the treatment of hereditary tyrosinaemia type-1 (HT-1)
• EC approved new dosing frequency for Orfadin
• FDA approved in-use storage at room temperature for Orfadin
• The first patient was randomised in the phase 2 study anaGO to evaluate efficacy and safety of anakinra for the treatment of acute gout
• New distribution agreement for Ammonul®

Financial summary Q1 2017 (Q1 2016)

• Total revenue was SEK 1,396 M (1,273), an increase of 10 per cent (6 per cent at CER)
• Product revenue was SEK 1,269 M (1,108), an increase of 15 per cent (10 per cent at CER)
• Gross margin was 74 per cent (74)*
• EBITA was SEK 406 M (502)
• Cash SEK 1,032 M (SEK 786 M as of 31 December 2016)
• Earnings per share 0.73 SEK (1.12)

* Gross margin in Q1 2016 and Q1 2017 impacted by one-time events, please see Q1 report for details.

“The strong first quarter results derive from the entire portfolio, with the launches of Elocta and Alprolix gaining significant momentum. From a development perspective we presented new long-term safety and efficacy data for Elocta and Alprolix, and we elected to include a novel long-acting sub-cutaneous factor 9-XTEN development candidate in our collaboration with Bioverativ,” says Sobi’s CEO and President Geoffrey McDonough, “Also, Orfadin received two important approvals during the quarter.”

Telephone conference

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, today at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Geoffrey McDonough, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference.

To participate in the telephone conference, please call:

UK: +44 203 008 9809

SE: +46 8 566 426 93

US: +1 855 831 5948

Live audience URL:
http://event.onlineseminarsolutions.com/r.htm?e=1397849&s=1&k=08548B2F4E60BFAC70B564C2463239A6

(The recording will be made available via the audience URL within three hours after the live broadcast.)  

Sobi's report for the first quarter 2017 can be found on http://www.sobi.com/Investors--Media/Financial-Reports/

---

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.  

For more information please contact 

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of Linda Holmström, Senior Communications Manager, at 08:00 am CET on 28  April 2017. 

Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00     www.sobi.com